Inflammation and incretins

Nutrient excess results in systemic inflammation in diabetes contributing to insulin resistance, dyslipidaemia and increased cardiovascular risk. GLP-1 agonists and DPP-4 inhibitors, which are now well accepted therapies for diabetes may play a unique role in modulating this inflammatory process. In...

Descripción completa

Detalles Bibliográficos
Autor principal: Hatwal, Amitabh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Mini Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603036/
https://www.ncbi.nlm.nih.gov/pubmed/23565388
http://dx.doi.org/10.4103/2230-8210.104049
Descripción
Sumario:Nutrient excess results in systemic inflammation in diabetes contributing to insulin resistance, dyslipidaemia and increased cardiovascular risk. GLP-1 agonists and DPP-4 inhibitors, which are now well accepted therapies for diabetes may play a unique role in modulating this inflammatory process. Incretin based therapies have shown beneficial anti-inflammatory effects on surrogate markers but cardiovascular outcome data is still lacking.

Ejemplares similares